Journal of Experimental Medicine

Journal of Experimental Medicine The Journal of Experimental Medicine publishes immunology, cancer, stem cells, microbial pathogenesis, vascular biology, and neurobiology research.

Since its inception in 1896, the goal of The Journal of Experimental Medicine (JEM) has been to publish outstanding and enduring studies in medical biology. At a time when many leading publishing groups are establishing topic-specific journals, we believe it is critical to complement that approach by offering a distinguished venue for publication of studies that integrate disciplines within the fi

eld of pathogenesis. A distinctive editorial system supports this goal with an emphasis on exceptional service to our authors. Two groups of editors work hand-in hand: professional editors with strong scientific backgrounds, and full-time practicing scientists. At least one editor from each group evaluates the merits of each paper prior to external review. The editors convene weekly to discuss all papers with external referee comments, and reach rapid decisions without excessive requests for revision. Within the field of medical biology we focus both on human studies and diverse in vivo experimental models of human disease that address such topics as genetics, inflammation, immunity, infectious disease, cancer, vascular biology, metabolic disorders, neuroscience, and stem cell biology. We welcome reports ranging from atomic-level analyses to clinical interventions that illustrate new mechanisms.

Iris Fagniez, Jean-Laurent Casanova, Rui Yang and colleagues identify new patients with inherited RORγT deficiency chara...
09/04/2026

Iris Fagniez, Jean-Laurent Casanova, Rui Yang and colleagues identify new patients with inherited RORγT deficiency characterized by impaired TCRα rearrangement, depletion of MAIT and iNKT cells, reduced numbers of TH17, TH1*, and CD8+ T cells, and defective IFN-γ and IL-17 immunity against Mycobacterium and Candida. https://hubs.la/Q04wM7p_0

Explore JEM's new collection highlighting the latest discoveries in     and  , timed to coincide with the Cold Spring Ha...
09/03/2026

Explore JEM's new collection highlighting the latest discoveries in and , timed to coincide with the Cold Spring Habor Asia meeting on Cancer Immunotherapy in Suzhou, China. The collection spans a broad range of topics including the therapeutic potential of targeting cDC1, a strategy to harness the immunosuppressive potential of inhibitory receptors, targeting of inhibitory receptor agonists, leveraging microbiota to improve immune checkpoint blockade therapies, and advances in CAR-T cell development.
👉 https://hubs.la/Q04v-DhK0

Luciana Conde, Valter Monteiro, Joao C.R. Freitas, Mauro M. Teixeira (UFMG - Universidade Federal de Minas Gerais), Caro...
09/02/2026

Luciana Conde, Valter Monteiro, Joao C.R. Freitas, Mauro M. Teixeira (UFMG - Universidade Federal de Minas Gerais), Carolina Lucas (Yale School of Medicine) and colleagues show that Qdenga vaccination induces serotype-skewed immunity shaped by both immune imprinting and the vaccine’s DENV-2 backbone, limiting balanced tetravalent responses, particularly in dengue-naïve individuals. https://hubs.la/Q04whcrc0

Journal of Experimental Medicine (JEM)'s new   activity in collaboration with MSK CME is now available! ✍️💻 https://hubs...
09/02/2026

Journal of Experimental Medicine (JEM)'s new activity in collaboration with MSK CME is now available! ✍️💻 https://hubs.la/Q04wgByM0New content📄: “Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine” (Conde et al. https://hubs.la/Q04wgmQ70)

What’s a Journal-Based CME activity? A full-text article that is free to read, a multiple-choice question test, and an evaluation/self-assessment 👉 https://hubs.la/Q04wgByM0

Yamato Sajiki, Koichi Araki et al. (Cincinnati Children's Research Foundation) reveal functional heterogeneity & plastic...
08/31/2026

Yamato Sajiki, Koichi Araki et al. (Cincinnati Children's Research Foundation) reveal functional heterogeneity & plasticity within naïve CD8 T cells, identifying functionally superior subsets that can emerge from less potent cells & drive robust immune responses thru. enhanced survival of effector progeny https://hubs.la/Q04vYdkT0

Hsin Chieh Wu, Marie-Claude Geoffroy, Hugues de Thé and colleagues (Collège de France) reveal that PML::RARA drives acut...
08/28/2026

Hsin Chieh Wu, Marie-Claude Geoffroy, Hugues de Thé and colleagues (Collège de France) reveal that PML::RARA drives acute promyelocytic by bridging the PML-bound SUMO machinery and RARA-bound corepressors, enhancing corepressor , target gene repression, and the differentiation block. https://hubs.la/Q04vHVM10

Dysregulated immune responses rather than damage by   burgdorferi alone induce  . Sachan et al. demonstrate that infecte...
08/24/2026

Dysregulated immune responses rather than damage by burgdorferi alone induce . Sachan et al. demonstrate that infected mice rapidly develop gut leakiness, endotoxemia, reduced -reactive antibodies, and systemic markers of https://hubs.la/Q04v4F030

Vaishali Aggarwal, Yangxi Sun, Chang Liu, Dario Vignali et al. (University of Pittsburgh) identify two distinct exhauste...
08/18/2026

Vaishali Aggarwal, Yangxi Sun, Chang Liu, Dario Vignali et al. (University of Pittsburgh) identify two distinct exhausted LAG3⁺CD8⁺ T cell subpopulations in tumors using a lineage-tracing model. One subset acts as a long-lasting progenitor population that maintains anti-tumor immunity and memory, supporting therapeutic strategies targeting LAG3⁺ exhausted T cells to improve tumor control.
https://hubs.la/Q04tmblz0

Viewpoint: Xie, Tebak, Pathak,  & Glass propose that persistent implant stress erodes lineage-defining regulatory progra...
08/14/2026

Viewpoint: Xie, Tebak, Pathak, & Glass propose that persistent implant stress erodes lineage-defining regulatory programs that preserve cell fate and state, uncoupling cellular compensation from tissue needs and driving regulatory drift, thereby reframing implant failure as a loss of adaptive tissue coordination rather than inflammation alone. https://hubs.la/Q04t36N50

Evans et al. identify CD1d as a key regulator of myeloid cell diversity in  . CD1d targeting reshapes tumor immune infil...
08/13/2026

Evans et al. identify CD1d as a key regulator of myeloid cell diversity in . CD1d targeting reshapes tumor immune infiltrates, suppresses tumor growth, & enhances efficacy, suggesting an actionable pathway for treatment. https://hubs.la/Q04sYMmh0

Address

950 3rd Avenue, Fl 2nd
New York, NY
10022

Alerts

Be the first to know and let us send you an email when Journal of Experimental Medicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Journal of Experimental Medicine:

Shortcuts

Share